Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
BISCAY trial (durvalumab): what clinicians have said so far
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
- NCT02546661 ↗
- Active, not recruiting
- AstraZeneca
- Deep size, estimated: 301+ verified statements once built
We haven't built an HCP commentary report on BISCAY (durvalumab plus fexagratinib (AZD4547); durvalumab plus olaparib; durvalumab plus adavosertib (AZD1775)) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on BISCAY so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 21 posts on X, typically up to 92 once built | |
| 1 podcast episode, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment (BISCAY).
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Muscle Invasive Bladder Cancer
- Interventions
- AZD4547; MEDI4736; Olaparib; AZD1775; Vistusertib; AZD9150; Selumetinib
- Arms
- Module A: AZD4547 Monotherapy · Experimental
- Module A: MEDI4736 (durvalumab) + AZD4547 · Experimental
- Module B: MEDI4736 (durvalumab) + Olaparib · Experimental
- Module C: MEDI4736 (durvaluamb) + AZD1775 · Experimental
- Module D: MEDI4736 (durvalumab) monotherapy · Experimental
- Module E: MEDI4736 (durvalumab) + Vistusertib · Experimental
- Module F: MEDI4736 (durvaluamb) + AZD9150 · Experimental
- Module G: MEDI4736 + Selumetinib · Experimental
- Enrollment
- 117
- Primary outcomes
- Module A: The frequency and nature of adverse events related to AZD4547 monotherapy.
- Module A: The frequency and nature of adverse events related to the combination of intravenous MEDI4736 (durvalumab) and oral AZD4547.
- Module B: The frequency and nature of adverse events related to the combination of intravenous MEDI4736 (durvalumab) and oral olaparib.
- Module C: The frequency and nature of adverse events related to intravenous MEDI4736 (durvalumab) when given in combination with oral AZD1775.
- Module D: The frequency and nature of adverse events related to intravenous MEDI4736 (durvalumab) monotherapy.
- Module E: The frequency and nature of adverse events related to intravenous MEDI4736 (durvalumab) when given in combination with oral vistusertib.
- Module F: The frequency and nature of adverse events related to the combination of intravenous MEDI4736 (durvalumab) and intravenous AZD9150.
- Module G: The frequency and nature of adverse events related to intravenous MEDI4736 (durvalumab) when given in combination with oral selumetinib.
- All Modules: Change from baseline in clinical chemistry parameters.
- All Modules: Change from baseline in haematology parameters.
- All Modules: Change from baseline in urinalysis results.
- All Modules: Change from baseline in vital signs.
- All Modules: Change from baseline in physical examination findings.
- All Modules: Change from baseline in ECG findings.
- All Modules: Change from baseline in ejection fraction determined by assessing ECHO/MUGA scans.
- All Modules: Change from baseline in coagulation parameters
- All Modules: Change from baseline in lipid profile
- Sponsor
- AstraZeneca
- Start
- Dec 28, 2016
- Primary completion
- Mar 18, 2020
- Results posted
- No
- Registry record
- NCT02546661 · updated Oct 1, 2026
Publications
linked from the registry- Powles T, Carroll D, Chowdhury S, Gravis G, Joly F, Carles J, Flechon A, Maroto P, Petrylak D, Rolland F, Cook N, Balar AV, Sridhar SS, Galsky MD, Grivas P, Ravaud A, Jones R, Cosaert J, Hodgson D, Kozarewa I, Mather R, McEwen R, Mercier F, Landers D. An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. Nat Med. 2021 May;27(5):793-801. doi: 10.1038/s41591-021-01317-6. Epub 2021 May 3. PubMed 33941921
- Maia MC, Salgia M, Pal SK. Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. Nat Rev Urol. 2020 May;17(5):271-291. doi: 10.1038/s41585-020-0297-9. Epub 2020 Mar 17. PubMed 32203306